{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:39:38Z","timestamp":1767980378484,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry Disease (FD) is a rare X-linked metabolic lysosomal disorder. FD has a broad range of symptoms which vary markedly between patients. The heterogenous nature of the disease makes diagnosis difficult for health care professionals (HCPs), which in turn has a significant effect on the patient\u2019s quality of life (QoL). As few adolescent patients are eligible for treatment, to date there has been little published data on the burden of disease and impact of treatment on these patients and their caregivers. This study was developed to provide some insight into these groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An online-based survey was performed to gather further insights on the burden of FD in 14 adolescents aged 12\u201315\u00a0years old across three European countries, from the perspective of the patients, caregivers and HCPs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Symptom burden was found to be high in the adolescent population, with \u2018pain\u2019 and \u2018intolerance to heat or cold\u2019 commonly reported symptoms, both by patients and to HCPs. Eleven of the 14 patients surveyed were receiving enzyme replacement therapy (ERT), with their post-ERT symptomology showing improvement when compared to symptoms before receiving ERT. The majority of caregivers believe their child\u2019s overall health has improved since starting ERT. While there was a positive outlook towards ERT noted by the patients and caregivers, 4\/5 HCPs believed there is \u2018a need for more efficacious treatment options\u2019 and all HCPs noted that there is \u2018a need for more manageable treatment options\u2019. FD was shown to place a burden on caregivers, who reported feelings of guilt and absences from work.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Data show there is a significant symptom burden for the adolescent, which affects their QoL and mental health, as well as placing a burden on the wider family. While ERT is an effective treatment and provides symptom relief for many of the respondents in the survey, they still reported symptom burden. Additionally, there was reporting of reluctance to engage in treatment or difficulties associated with the treatment. Heterogeneity in symptom presentation suggests that the treatment regimen needs to be tailored to the individual. Physicians therefore need to have a choice of treatment options available to help them manage symptoms and disease where the benefit to risk ratio is in favour of undergoing treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02417-3","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T17:08:01Z","timestamp":1657904881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Burden associated with Fabry disease and its treatment in 12\u201315\u00a0year olds: results from a European survey"],"prefix":"10.1186","volume":"17","author":[{"given":"Lisa","family":"Bashorum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"McCaughey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley C.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-9063","authenticated-orcid":false,"given":"Alasdair","family":"MacCulloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"issue":"3","key":"2417_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"issue":"1","key":"2417_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5(1):30.","journal-title":"Orphanet J Rare Dis"},{"key":"2417_CR3","first-page":"88","volume":"12","author":"AS Thomas","year":"2014","unstructured":"Thomas AS, Hughes DA. Fabry Disease. Pediatric Endocrinol Rev (PER). 2014;12:88\u2013101.","journal-title":"Pediatric Endocrinol Rev (PER)"},{"issue":"5","key":"2417_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ. Migalastat: A review in fabry disease. Drugs. 2019;79(5):543\u201354.","journal-title":"Drugs"},{"issue":"2","key":"2417_CR5","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/OPX.0b013e31827ec7eb","volume":"90","author":"MD Sivley","year":"2013","unstructured":"Sivley MD. Fabry disease: a review of ophthalmic and systemic manifestations. Optom Vis Sci. 2013;90(2):e63-78.","journal-title":"Optom Vis Sci"},{"key":"2417_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1750-1172-8-116","volume":"8","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Sanchez-Ni\u00f1o MD, Politei J, Oliveira JP, Wanner C, Warnock DG, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8:116.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2417_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539\u201348.","journal-title":"Genet Med"},{"issue":"1\u20132","key":"2417_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","volume":"344","author":"R El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD. Fabry\u2019s disease. J Neurol Sci. 2014;344(1\u20132):5\u201319.","journal-title":"J Neurol Sci"},{"issue":"19","key":"2417_CR9","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","volume":"119","author":"BL Thurberg","year":"2009","unstructured":"Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O\u2019Callaghan MW. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation. 2009;119(19):2561\u20137.","journal-title":"Circulation"},{"issue":"3","key":"2417_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122(3):19\u201327.","journal-title":"Mol Genet Metab"},{"key":"2417_CR11","doi-asserted-by":"crossref","unstructured":"Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S (2015) Newborn screening for lysosomal storage disorders. Seminars in perinatology 39(3): 206.","DOI":"10.1053\/j.semperi.2015.03.005"},{"key":"2417_CR12","doi-asserted-by":"crossref","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later\u2010onset GLA mutation c. 936+ 919G> A (IVS4+ 919G> A). Human mutation. 2009;30(10):1397\u2013405.","DOI":"10.1002\/humu.21074"},{"issue":"1","key":"2417_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2417_CR14","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and nonclassical Fabry disease: A multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2417_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008;64(5):550\u20135.","journal-title":"Pediatr Res"},{"issue":"5","key":"2417_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/gim.2014.120","volume":"17","author":"DA Laney","year":"2015","unstructured":"Laney DA, Peck DS, Atherton AM, Manwaring LP, Christensen KM, Shankar SP, et al. Fabry disease in infancy and early childhood: a systematic literature review. Genet Med. 2015;17(5):323\u201330.","journal-title":"Genet Med"},{"issue":"2","key":"2417_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","volume":"117","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Jefferies JL, Laney DA, Lawson VH, Mauer M, Taylor MR, et al. The management and treatment of children with Fabry disease: A United States-based perspective. Mol Genet Metab. 2016;117(2):104\u201313.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2417_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184\u201392.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2417_CR19","first-page":"189","volume":"64","author":"HM Mahmud","year":"2014","unstructured":"Mahmud HM. Fabry\u2019s disease\u2013a comprehensive review on pathogenesis, diagnosis and treatment. J Pak Med Assoc. 2014;64(2):189\u201394.","journal-title":"J Pak Med Assoc"},{"issue":"11","key":"2417_CR20","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00431-009-0937-9","volume":"168","author":"G Pintos-Morell","year":"2009","unstructured":"Pintos-Morell G, Beck M. Fabry disease in children and the effects of enzyme replacement treatment. Eur J Pediatr. 2009;168(11):1355\u201363.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2417_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ymgme.2013.03.008","volume":"109","author":"MG Bouwman","year":"2013","unstructured":"Bouwman MG, de Ru MH, Linthorst GE, Hollak CE, Wijburg FA, van Zwieten MC. Fabry patients\u2019 experiences with the timing of diagnosis relevant for the discussion on newborn screening. Mol Genet Metab. 2013;109(2):201\u20137.","journal-title":"Mol Genet Metab"},{"issue":"11","key":"2417_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769\u201375.","journal-title":"J Med Genet"},{"issue":"11","key":"2417_CR23","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750\u201360.","journal-title":"J Med Genet"},{"key":"2417_CR24","unstructured":"M\u00fcller MJ. Chapter 29. Neuropsychiatric and psychosocial aspects of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford, UK: Oxford Pharmagenesis; 2006."},{"key":"2417_CR25","unstructured":"(EMA) EMA. Galafold: EPAR - Product information 2021 [updated 27th Aug 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/galafold-epar-product-information_en.pdf."},{"key":"2417_CR26","unstructured":"European Medicines Agency (EMA). Fabrazyme (agalsidase beta) Summary of product characteristics (SmPC). Genzyme Ireland Ltd. 2020 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fabrazyme-epar-product-information_en.pdf."},{"key":"2417_CR27","unstructured":"European Medicines Agency (EMA). Replagal (agalsidase alfa)) summary of product characteristics (SmPC). Shire human genetic therapies AB. 2017 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en.pdf."},{"issue":"4","key":"2417_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ymgme.2019.02.005","volume":"126","author":"H Sasa","year":"2019","unstructured":"Sasa H, Nagao M, Kino K. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing surveillance in Japan. Mol Genet Metab. 2019;126(4):448\u201359.","journal-title":"Mol Genet Metab"},{"key":"2417_CR29","unstructured":"(FDA) FaDA. Fabrazyme Product information [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103979s5135lbl.pdf"},{"issue":"6","key":"2417_CR30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Wyatt KM, Henley W, Nikolaou V, Waldek S, Hughes DA, et al. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):969\u201378.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2417_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75(1):65\u201374.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2417_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173358","volume":"12","author":"R El Dib","year":"2017","unstructured":"El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS ONE. 2017;12(3): e0173358.","journal-title":"PLoS ONE"},{"key":"2417_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006663.pub4","author":"R El Dib","year":"2016","unstructured":"El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Systematic Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.CD006663.pub4.","journal-title":"Cochrane Database Systematic Rev"},{"issue":"4","key":"2417_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","volume":"152","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatrics. 2008;152(4):563\u201370.","journal-title":"J Pediatrics."},{"issue":"1","key":"2417_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24(1):137\u201348.","journal-title":"J Am Soc Nephrol"},{"key":"2417_CR36","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2147\/DDDT.S102761","volume":"10","author":"O Goker-Alpan","year":"2016","unstructured":"Goker-Alpan O, Longo N, McDonald M, Shankar SP, Schiffmann R, Chang P, et al. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are na\u00efve to enzyme replacement therapy. Drug Des Devel Ther. 2016;10:1771\u201381.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2417_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","volume":"96","author":"U Ramaswami","year":"2007","unstructured":"Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr. 2007;96(1):122\u20137.","journal-title":"Acta Paediatr"},{"issue":"455","key":"2417_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1651-2227.2007.00216.x","volume":"96","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr. 2007;96(455):84\u20136.","journal-title":"Acta Paediatr"},{"issue":"5","key":"2417_CR39","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","volume":"83","author":"L Borgwardt","year":"2013","unstructured":"Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard LA. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83(5):432\u20138.","journal-title":"Clin Genet"},{"issue":"3","key":"2417_CR40","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","volume":"126","author":"M Spada","year":"2019","unstructured":"Spada M, Baron R, Elliott PM, Falissard B, Hilz MJ, Monserrat L, et al. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease\u2013a systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126(3):212\u201323.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2417_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019;96(2):107\u201317.","journal-title":"Clin Genet"},{"issue":"14","key":"2417_CR42","doi-asserted-by":"publisher","first-page":"892","DOI":"10.12968\/bjon.2010.19.14.49047","volume":"19","author":"R Parini","year":"2010","unstructured":"Parini R, Pozzi K, Di Mauro S, Furlan F, Rigoldi M. Intravenous enzyme replacement therapy: hospital vs home. Br J Nurs. 2010;19(14):892\u20134.","journal-title":"Br J Nurs"},{"issue":"6","key":"2417_CR43","doi-asserted-by":"publisher","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","volume":"15","author":"A Milligan","year":"2006","unstructured":"Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006;15(6):330\u20133.","journal-title":"Br J Nurs"},{"issue":"3","key":"2417_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","volume":"94","author":"AC Vedder","year":"2008","unstructured":"Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008;94(3):319\u201325.","journal-title":"Mol Genet Metab"},{"key":"2417_CR45","doi-asserted-by":"publisher","unstructured":"Orenius T, LicPsych, S\u00e4il\u00e4 H, Mikola K, Ristolainen L. Fear of injections and needle phobia among children and adolescents: an overview of psychological behavioral and contextual factors. SAGE Open Nursing. 2018;https:\/\/doi.org\/10.1177\/2377960818759442.","DOI":"10.1177\/2377960818759442"},{"issue":"2\u20133","key":"2417_CR46","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0304-3959(99)00236-5","volume":"84","author":"MJ Hilz","year":"2000","unstructured":"Hilz MJ, Stemper B, Kolodny EH. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain. 2000;84(2\u20133):361\u20135.","journal-title":"Pain"},{"issue":"2","key":"2417_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","volume":"37","author":"FE Bolsover","year":"2014","unstructured":"Bolsover FE, Murphy E, Cipolotti L, Werring DJ, Lachmann RH. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis. 2014;37(2):177\u201387.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 3","key":"2417_CR48","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1007\/s10545-009-9025-6","volume":"33","author":"DA Laney","year":"2010","unstructured":"Laney DA, Gruskin DJ, Fernhoff PM, Cubells JF, Ousley OY, Hipp H, et al. Social-adaptive and psychological functioning of patients affected by Fabry disease. J Inherit Metab Dis. 2010;33(Suppl 3):S73-81.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2417_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1477-7525-10-116","volume":"10","author":"U Ramaswami","year":"2012","unstructured":"Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, et al. Measuring patient experiences in Fabry disease: validation of the Fabry-specific pediatric health and pain questionnaire (FPHPQ). Health Qual Life Outcomes. 2012;10(1):116.","journal-title":"Health Qual Life Outcomes"},{"key":"2417_CR50","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3389\/fpsyg.2019.01780","volume":"10","author":"P Cardinali","year":"2019","unstructured":"Cardinali P, Migliorini L, Rania N. The caregiving experiences of fathers and mothers of children with rare diseases in Italy: Challenges and social support perceptions. Front Psychol. 2019;10:1780.","journal-title":"Front Psychol"},{"key":"2417_CR51","unstructured":"Hiwot T, Hughes D, Ramaswami U. BIMDG: Guidelines for the treatment of Fabry Disease 2020 [Available from: http:\/\/www.bimdg.org.uk\/store\/lsd\/\/FabryGuide_LSDSS_Jan2020_700523_11032020.pdf."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02417-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02417-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02417-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T18:08:54Z","timestamp":1657908534000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02417-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2417"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02417-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was qualified for exemption from the need for IRB review by the Ethical and Independent Review Services. In line with IRB and BHBIA guidance, all respondents provided informed consent before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LB, GM and AM are employees of Amicus Therapeutics who manufacture Galafold\u2122. OE, ACH and RP are employees of Adelphi Values PROVE who were contracted by Amicus Therapeutics to carry out the study and to support with medical writing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}